Objective: Acid-labile subunit deficiency (ACLSD), caused by inactivating mutations in both IGFALS gene alleles, is characterized by marked reduction in IGF-I and IGFBP-3 levels associated with mild growth retardation. The aim of this study was to expand the known phenotype and genetic characteristics of ACLSD by reporting data from four index cases and their families.
| INTRODUCTION
Acid-labile subunit deficiency (ACLSD; OMIM #615961), caused by inactivating mutations in both IGFALS gene alleles, is characterized by severely reduced circulating levels of IGF-I and IGFBP-3 associated with mild growth retardation (height −2 to −3 standard deviation score
[SDS]). 1 The condition is transmitted with an autosomal recessive pattern of inheritance in both consanguineous and nonconsanguineous families. 2 About 30 patients from diverse ethnic backgrounds have been reported worldwide. [3] [4] [5] [6] Because acid-labile subunit (ALS) is essential for the stability of ternary complex with IGF-I and IGFBP-3 (or IGFBP-5), 7 the lack of this protein results in the absence of the 150-kDa complex in the circulation and the instability of IGF-I and IGFBP-3.
ACLSD patients present a lack of response to the acute and chronic administration of recombinant human GH (rhGH), both in terms of height velocity acceleration and increase in IGF-I levels. 1, 3, [8] [9] [10] [11] Pubertal delay and insulin insensitivity, have been frequently reported. 3 We evaluated the impact on height and on the IGF system of different IGFALS gene variants characterized in four families with ACLSD. The study of these families confirms previous findings such as a marked reduction in circulating levels of IGF-I, and a more severe reduction in IGFBP-3 levels, associated with mild growth impairment.
Functional characterization for several of the IGFALS variants found in these patients has been previously reported. 12, 13 The effect of one combined variant, still unreported, on the synthesis and secretion of ALS by in vitro expression, was also evaluated.
| SUBJECTS AND METHODS
In the four index cases, clinical examination and routine laboratory analysis ruled out nonendocrinological causes of short stature. Evaluation of the GH-IGF axis revealed normal GH response to stimulation tests with low levels of IGF-I and low or undetectable IGFBP-3 and ALS levels. Evaluation of other pituitary axes was normal (Table S1 ).
| Cases descriptions

| Family 1
The proband (IV-4, Figure 1 ), a 13.8-year-old prepubertal boy referred for growth retardation, was born at term (Table S1 ), the fourth of nine siblings from consanguineous parents (first-degree cousins) of short normal height ( In patient IV-2 from family 1, biochemical profile was evaluated at the age of 22 y. Growth charts of ACLSD subjects are included in Supplementary Figures: subjects IV-4, IV-3 and IV-8 from family 1 as Figures S1, S5 and S6, respectively; subject II-1 from family 2 as Figure S2 ; subject II-2 from family 3 as Figure S3 ; and subject III-2 from family 4 as Figure S4 . Figure S1 ).
| Family 2
The index case (II-1, Figure 1 ) was a 5.0-year-old girl, born at term (Table S1 ). She was the only child of nonrelated healthy parents of normal height (Table 1) . Her height was within normal limits, slightly below her target height (TH −0.73; Figure S2 ). She presented a 46,XX karyotype, a delayed bone age (3.5 years) and a normal brain MRI.
| Family 3
The index case was a 4.7-year-old boy (II-2, Figure 1 ). He was born at term (Table S1 ), the second child of healthy, nonconsanguineous parents of normal height ( ( Figure S3 ).
| Family 4
The index case (III-2, Figure 1 ), a 2.4-year-old boy, was referred for short stature evaluation (Table 1 and Figure S4 ). He was born at 39 weeks of gestation, the second child from nonconsanguineous parents (Table S1 ). While his mother (II-8) and his 6-year-old brother (III-1) presented normal height, his father (II-4) was also short (Table 1) .
While families 1 and 4 were evaluated at the "Ricardo Gutiérrez"
Children′s Hospital (Buenos Aires, Argentina), families 2 and 3, both living in Brazil, were evaluated at Federal University of Sao Paulo, (Brazil). Other studies were all performed at the "Ricardo Gutiérrez"
Children′s Hospital. Auxological data, biochemical and genetic studies
were also extended to all available relatives ( Table 1) .
The study was conducted in accordance with the Helsinki Declaration. The Ethics Committee of the "Ricardo Gutiérrez" Hospital approved the protocol. The patients gave their assent and parents and relatives signed a written informed consent for molecular studies.
| Endocrinological evaluation
Serum levels of GH, IGF-I and IGFBP-3 and antithyroperoxidase antibodies were determined by chemiluminescent immunometric assays (Immulite 2000, Siemens Healthcare Diagnostics, Llamberis, Gwynedd, UK). TSH, free T4 (FT4), ACTH, cortisol, PRL, LH, FSH, testosterone and insulin were measured by electrochemiluminescence (Cobas e411
analyzer; Roche Diagnostics GmbH, Mannheim, Germany). Serum ALS levels were evaluated by enzyme-linked immunosorbent assay (ELISA, Mediagnost, Reutlingen, Germany). IGF-I response to exogenous rhGH was also evaluated (Table S2 ).
| Molecular studies
Genomic DNA was isolated as previously described. 14 
| Site-directed mutagenesis and transient transfection assays
Mutants ALS (p.Leu409Phe, pAla475Val and the double mutant p.[Leu409Phe;Ala475Val]-ALS) were generated into an expression vector containing the wild type (WT) IGFALS cDNA (pCMV6-XL5-hIGFALS, Origene, Rockville, USA), using the QuikChange II XL SiteDirected Mutagenesis Kit (Agilent Technologies, Santa Clara, CA, USA) as previously described.
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Transfections were performed using Chinese hamster ovarian (CHO) cells as previously described and lysates and conditioned media (CM) were collected 48 hours after transfection for WIB analysis. 
| In vitro ternary complex formation (ivTCF)
In vitro ternary complex formation (ivTCF) was evaluated by size exclusion chromatography. In family 1, using 
| RESULTS
| Biochemical profile
All index cases presented normal stimulated GH, low IGF-I and extremely low or undetectable IGFBP-3 and ALS levels ( Table 1, Table   S1 ). Severe IGF-I deficiency with undetectable levels of IGFBP-3 and ALS was also found in four relatives: two siblings in family 1 (IV-3 and IV-8), the father (II-4) and the paternal aunt (II-5) in family 4 (Table 1 and Figure 1 ). IGF generation test was performed in index cases from families 2, 3 and 4 (Table S2 ). Responses of IGF-I and IGFBP-3 to rhGH administration were low or absent. One father (II-4, family 4), presented a subnormal increase in IGF-I levels with no changes in either IGFBP-3 or ALS levels (Table S2 ).
| Sequence analysis of the IGFALS gene
Sequencing of the IGFALS gene revealed that all four index cases were either homozygous or compound heterozygous for a presumably pathogenic IGFALS gene variant (Table 1) turned out to present the same genotype as the father (Table 1 , Figure 1 ).
| Gene dosage effect
Height as well as IGF-I, IGFBP-3 and ALS were significantly different among ACLSD patients, HC and WT subjects. Although these parameters were only significantly lower in ACLSD compared to WT relatives, ACLSD and HC showed height, IGF-I, IGFBP-3 and ALS levels significantly below zero SDS, suggesting a gene dosage effect (Table 2 ). 
| Western immunoblot (WIB)
Serum
T A B L E 2 Height and IGF-I, IGFBP-3 and acid-labile subunit (ALS) levels in subjects with ALS deficiency (ACLSD), heterozygous carriers (HC) and wild type (WT)
ACLSD
| In vitro ternary complex formation (ivTCF)
Profiles corresponding to ivTCF are shown in Figure 3 . In family 1, ivTCF was performed with the addition of 6 μg/mL rhIGFBP-3 on Sephacryl column. 13 In subjects presenting ACLSD (IV-3, IV-4
and IV-8), no peak corresponding to the ternary complex was detected, with most of the complexed 125 I-IGF-I eluting in the 50-kD peak corresponding to the binary complex formed with IGFBPs.
Heterozygous carriers (III-1, III-2, IV-5, IV-6 and IV-7) presented peaks corresponding to ternary and binary complex of similar magnitude, while the only homozygous WT subject from this family (IV-1)
showed a predominant 150-kD peak corresponding to the ternary complex.
In the other three families, ivTCF was performed on Superdex-200 columns. Patient II-1 (family 2) showed no detectable 150-kD peak and her parents had both a clear peak corresponding to ternary complexes. In family 3, patient II-2 presented a reduced but detectable ternary complex, while his parents and his older sister all presented predominant ternary complex peaks.
In family 4, size-exclusion chromatography revealed absence of 150-kD peak in the three ACLSD subjects (III-2, II-4, and II-5; Figure 3 , panel A), whereas normal ternary complexes were observed in HC (I-2, II-8, and III-1) as well as in the only homozygous WT subject from this family (II-6; Figure 3 , panel B). (Table 3) .
| IGFALS polymorphism analysis
| DISCUSSION
In the present study, we have characterized ACLSD in four children presenting either short stature, normal stature but shorter than midparental height, or even normal height adequate to familial height.
All cases presented normal GH-stimulated levels and severe IGF-I and IGFBP-3 deficiencies. Despite this variable impact on postnatal growth, the lack of ALS had a consistent effect on the circulating IGF system resulting in diminished levels of IGF-I with a more severe reduction in IGFBP-3. plete ACLSD have been characterized. [3] [4] [5] [6] In autosomal recessive genetic diseases, patients arise usually in consanguineous families being both parents' carriers for the same pathogenic variants. However, in ACLSD more than 40% of the patients reported were compound heterozygous for two different variants inherited from nonrelated parents. 2 This finding suggests that pathogenic IGFALS variants could be present in the general population, probably because they would not be under a strong negative selection pressure. Our previous finding of heterozygous inactivating IGFALS variants in idiopathic short stature and even in normal control children, support this interpretation.
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Reinforcing this observation, three of four index cases from this study were compound heterozygous for different IGFALS gene variants, while their parents, obligate HC, were nonrelated. Only in family 1, the parents were first-degree cousins, carrying the same genetic variants.
Characterization of two ACLSD undiagnosed siblings in family 1, and the finding of two ACLSD adults in family 4, underline the importance to extend biochemical and genetic studies to all available relatives. Because ACLSD subjects could present a mild phenotype, it is not unusual to find undiagnosed ACLSD siblings and even adults. I-IGF-I. In family 1, ivTCF was performed with the addition of 6 μg/mL rhIGFBP-3 on Sephacryl columns. In families 2, 3 and 4, ivTCF was performed on Superdex-200 columns. The 150-kDa peak corresponds to ternary complex (TC), the 30-50-kDa peak to binary complexes and the 7-kDa peak to unbound We found five different alleles ranging from 10 to 15 CA-repeats for the D16S3034 microsatellite, while for the D16S3024 microsatellite, eight different alleles ranging from 21 to 31 CA-repeats, were detected.
All of IGF-I levels (88 ng/mL, −0.98 SDS) and measurable IGFBP-3 levels (1.0 μg/mL, −3.27 SDS). It could be speculated that this increase in IGF-I levels could be responsible for the observed growth acceleration.
Previously, we reported the impact of seven different IGFALS variants found in these families by in vitro expression. was not expressed in vitro, indicating that the pathogenicity of this double variant is caused by p.Leu409Phe variant.
In conclusion, this study not only confirms previous findings of ACLSD, but also reveals novel aspects such as: (i) the first report of a father-to-son transmission, not as a consequence of an autosomal dominant pattern of inheritance (the father was compound heterozygous and the mother HC for different IGFALS variants); (ii) male fertility is preserved in this condition; and (iii) ACLSD children retaining some ALS expression, may increase IGF-I on rhGH treatment. Whether this might improve adult height, remains to be determined.
